GSK’786

Showing 1 posts of 1 posts found.

GSK moves Crohn’s disease drug into phase III

January 14, 2011
Research and Development ChemoCentryx, Crohn’s disease, GSK’786, GlaxoSmithKline, Traficet-EN

GlaxoSmithKline and its partner ChemoCentryx have started late-stage trials of GSK’786 for Crohn’s disease. The initial study is a randomised, …

The Gateway to Local Adoption Series

Latest content